---
figid: PMC9360236__ajcr0012-2966-f4
pmcid: PMC9360236
image_filename: ajcr0012-2966-f4.jpg
figure_link: /pmc/articles/PMC9360236/figure/fig04/
number: Figure 4
figure_title: ''
caption: 'ITGB1-DT overexpression was associated with dismal prognosis in NSCLC as
  determined using the K-M survival analysis. A-C. OS, DSS, and PFI for NSCLC patients;
  D-F. OS, DSS, and PFI for LUAD patients; G-I. OS, DSS, and PFI for LUSC patients.
  Note: NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous
  cell carcinoma; K-M, Kaplan-Meier; OS, overall survival; DSS, disease specific survival;
  PFI, Progress free survival.'
article_title: Interfering with ITGB1-DT expression delays cancer progression and
  promotes cell sensitivity of NSCLC to cisplatin by inhibiting the MAPK/ERK pathway.
citation: Dan Li, et al. Am J Cancer Res. 2022;12(7):2966-2988.
year: '2022'

doi: ''
journal_title: American Journal of Cancer Research
journal_nlm_ta: Am J Cancer Res
publisher_name: e-Century Publishing Corporation

keywords:
- ITGB1-DT
- MAPK
- NSCLC
- overall survival
- disease-specific survival
- progression-free interval

---
